2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Update on Targeted Therapy in mNSCLC: Is Trastuzumab Deruxtecan a Promising New Therapy for HER2+? How Beneficial Is Erlotinib + Bevacizumab in EGFR+ Disease?

76 views
August 24, 2020
Comments 0
Login to view comments. Click here to Login